Biocon Biologics bags multiple market access for its biosimilar drug Yesintek

Biocon Biologics’ Yesintek has already been approved by major Pharmacy Benefit Managers (PBMs) & Insurers in the US | Photo Credit: DHIRAJ SINGH Biocon Biologics, a biosimilars company and subsidiary of Biocon Ltd, secured multiple market access agreements for Yesintek, a biosimilar to Stelara, used for the treatment of common chronic autoimmune diseases such as Crohn’s…